Rituximab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Rituximab
201 articles · page 8 of 17…ment with low dose prednisolone, mycophenolate, tocilizumab and nifedipine with partial control of her disease. She was on regular follow-…
… dose glucocorticoids and immunosuppressants, 45 (68%) received rituximab (RTM) at cumulative dose 2.4±1.5 grams. The level of TNF-alpha …
P.211 Ruxolitinib therapy in pansclerotic morphea refractory to autologous stem-cell transplantation
… kinase (JAK) – STAT signalling in PSM pathogenesis, suggesting ruxolitinib, a JAK 1/2 inhibitor, as potential therapeutic option [N Engl J…
… loss and worsening inflammatory arthralgias despite successive methotrexate dose escalations. Cardiopulmonary assessment revealed nonspecif…
…. The mean disease duration was 7.4±6.4 years. All pts received prednisolone at mean dose of 10±4 mg/day. 11% of patients received cyclophos…
…tremities (71% knees), and 1 facial lesion. Treatments included prednisone (76%), mycophenolate mofetil (64%), endothelin receptor antagon…
… exchange (TPE), cyclophosphamide, and maintenance therapy with mycophenolate mofetil or rituximab in cases of intolerance. Samples were obtained at …
… AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen cons…
…All patients received cyclophosphamide and/or advanced therapy (Rituximab/Tocilizumab) before transplantation; three of them did not requ…
…trials were randomized, and just one used an active comparator (rituximab). Mostly early diffuse cutaneous SSc (dcSSc) were eligible for …
… mean disease duration was 6.3±4.9 years. All patients received prednisolone at mean dose of 10.5±4.2 mg/day. 10% of patients received cyclo…